Teva Pharma Boosts FY23 Revenue Outlook - Update

(RTTNews) - While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.

For fiscal 2023, the company still projects adjusted earnings in a range of $2.25 to $2.55 per share, but now expects revenues between $15.1 billion and $15.5 billion, up from the prior forecast range between $15.0 billion and $15.4 billion.

On average, 11 analysts polled by Thomson Reuters expect the company to report earnings of $2.28 per share on revenues of $15.14 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com